{"id":"NCT02905331","sponsor":"Janssen Research & Development, LLC","briefTitle":"Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) Delivered Via a SelfDose (TM) Device in the Treatment of Subjects With Moderate to Severe Plaque-Type Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-28","primaryCompletion":"2018-02-06","completion":"2018-02-06","firstPosted":"2016-09-19","resultsPosted":"2018-09-06","lastUpdate":"2025-02-04"},"enrollment":78,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Guselkumab","otherNames":["CNTO 1959"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Group 1 (Guselkumab: Placebo)","type":"EXPERIMENTAL"},{"label":"Group 2 (Placebo: Guselkumab)","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the efficacy, safety, pharmacokinetics, immunogenicity, usability, and acceptability of guselkumab delivered using SelfDose device in participants with moderate to severe plaque-type psoriasis.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Placebo","deltaMin":0,"sd":null},{"arm":"Guselkumab","deltaMin":80.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":14,"countries":["United States","Canada","Poland"]},"refs":{"pmids":["37906417","30887876"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Injection Site Pain","Injection Site Coldness","Injection Site Pruritus","Injection Site Erythema","Injection Site Induration"]}}